Opportunities in China
(Presented in English)
Due to the high skyrocketing new drug development costs, low productivity
and drug pricing pressure, global pharmaceutical and biotech companies are
turning to China and India to conduct lower-cost R & D. The costs for new
drug development in Asia are generally much lower that that in the US and Europe.
For instance, the average cost for pre-clinical development in China is only
20% of that in the U.S. The fast growing economy, reformed healthcare system,
the large population and a rapidly aging population in China, and coupling
with recently built and upgraded pharmaceutical and biotech facilities, increased
experienced clinical trial sites, and greatly improved understanding of GLP,
GCP and GMP procedures, as well as the retuning of a large number of overseas
well educated, trained technical and professional people are the largest drives
for the consideration of conducting new drug R & D in China. With
current difficulty in raising traditional funds for a start-up or developing
stage mid and small pharmaceutical and biotech companies who have early stage
drug development programs, low cost considerations are even more critical for
business development and growth. In this presentation I will discuss my personal
observations how Chinese pharmaceutical and biotech industry has rapidly transformed
into a major global player of pharmaceutical R & D recently and provided
vast opportunities for ventures and new business opportunities in China. I
will present you some pro and con in outsourcing of pharmaceutical R & D
to China and the business opportunities in China.
Speaker: Dr. Ken Chang, bio: http://www.nc-cba.org/bios/kenchang.htm
Dr. Chang was the founder, the President, CEO and Chairman of the Board of
former Ardent Pharmaceuticals, Inc., Durham, North Carolina. He has raised
approximately $35 million since the inception of Ardent Pharmaceuticals in
1995. Ardent Pharmaceuticals, Inc. was recently merged with Enhance Biotech,
Inc., a public company. Dr. Chang’s new title for the Enhance Biotech,
Inc. is the Chief Scientific Officer and President Asia-Pacific Operations.
He currently holds an Adjunct Professor appointment in the Department of Anesthesiology,
Duke University Medical Center, Durham, North Carolina. He was a Principal
Scientist at former Burroughs Wellcome Co. He is the co-inventor for 8 issued
US patents and 8 pending US patents. Dr. Chang has published approximately
200 papers. He is a co-editor of the book entitled “The Delta Receptor” published
by Marcel Dekker, Inc. in 2004. He is an internationally recognized expert
in receptor pharmacology, biochemistry and molecular biology. He pioneered
in the discovery of delta receptors, delta receptor-selective compounds and
the understanding of physiological functions of the delta receptors. Dr. Chang
received his Bachelor of Science degree in Pharmacy from the School of Pharmacy,
National Taiwan University in Taipei, Taiwan and his Ph.D. degree in Biochemical
Pharmacology from the State University of New York at Buffalo, and his postdoctoral
training in Medical School, Johns Hopkins University.
Cost: FREE for NCCBA Regular members. You can join NCCBA and become a member
at this seminar. $10 suggested donation for non-members if you feel like the
seminar is beneficial to you. Donation will be used for covering drink, snacks
and other cost associated
When: 7:00-9:00 pm, Saturday, September 10, 2005. We will have half-hour of
networking social before (starting 6:30pm) and after the seminar. Come early
to meet your old and new friends.
MCNC, MCNC Auditorium
3021 Cornwallis Road,
Research Triangle Park, NC 27709-2889
Map and Directions: http://www.mcnc.org/rtpmap.html
1. Directions from Raleigh or locations south or east of RTP. (Please reference
Take I-40 West, toward Chapel Hill/Durham. Take the Durham Freeway (Route
147) North, the sign reads "Exit #279B, 147 North, Durham." Take
the next exit (to the right) marked "Research Triangle Park, Cornwallis
Road." At the end of the exit, turn right onto Cornwallis Road. Continue
after the first light (entrances to GlaxoSmithKline to both the right and left)for
about 0.2 miles - the sign of the entrance to MCNC is on the right-hand side.
The MCNC auditorium is next to the front entrance of the building.
2. Directions from Durham, Chapel Hill, or locations north or west of RTP:
(Please reference Map:http://www.mcnc.org/durham.html)
Take I-85 to the Durham Freeway (Route 147). Take the Durham Freeway (Route
147) South to the Cornwallis Road Exit. At the end of the ramp, make right
turn on to Cornwallis Road. Go through the first light if it was not red (entrances
to GlaxoSmithKline to both the right and left), and continue for about 0.2
miles - the entrance to MCNC is on the right-hand side, just after the yellow "Signal
Ahead" sign.The MCNC auditorium is next to the front entrance of the building.
North Carolina Chinese Business Association (NCCBA: www.nc-cba.org) is a premier
nonprofit charitable and educational business organization. NCCBA’s mission
is to represent, serve, and promote the common interests of our membership
and the North Carolina Chinese business community, particularly in promoting
entrepreneurial and corporate development related to sciences and technologies.
NCCBA will serve as a forum for networking and exchanging, for advancing our
knowledge in creating and sustaining successful businesses, and for encouraging
and facilitating coaching and consultation among our members. NCCBA will also
serve as a major catalyst in bridging the China - North Carolina business relationship.
Per requests, NCCBA will accept membership application on the site before
and after the seminar. We encourage professionals and entrepreneurs to join
this exciting non-profit organization. You will be invited to members-only
networking social events, receptions and seminars among many other benefits.
Please call (919) 345-6294 or (919) 481-3038 if you have any question on membership.
More information about NCCBA is available at http://www.nc-cba.org